GLP-1 Receipts is a Speculan LLC property. It is a price-verification record for FDA-approved GLP-1 medications in the United States. It publishes what sellers print, with dates, and makes no medical claims.
The record covers manufacturer direct-pharmacy programs (LillyDirect, NovoCare), TrumpRx, savings cards, Medicare arrangements and major telehealth programs. Every row carries its own as-of date and a link to the seller page the figure was read from. An hourly monitor reports on the front page how many published figures are still printed at their sources.
How the figures are checked
Automation gathers and monitors; people verify. A monitor re-reads every source page hourly and reports what it finds, but it cannot change a published number. Only a dated human pass can do that, and every change lands in a public change log with the date it was made.
Where a seller does not print a figure, the row is published unpriced rather than filled in. The methodology is public on the property itself.
What this is not
- Not medical advice, and no outcome claims.
- Not a pharmacy, a prescriber, or a seller of medication.
- No coverage of compounded products.
- No paid placement: commissions never affect rankings or displayed prices.
- No founder byline. Published under the company name.
Desk
GLP-1 Receipts operations: info@glp1receipts.com
Registered office: Speculan LLC, 30 N Gould St, Ste R, Sheridan, WY 82801, United States.